BioSpace News Archive

SenesTech, Inc., the leader in fertility control to manage animal pest populations, announces the expansion of EvolveTM, its innovative soft bait fertility control solution, into the broader market of open field agriculture.

Techsomed Medical Technologies LTD is thrilled to announce that FDA has granted De Novo clearance for its BioTraceIO, a groundbreaking ultrasound-based liver ablation software - designed for T issue Response Prediction.

Moderna, Inc. announced business updates and progress on the Company’s pipeline of transformative mRNA medicines.

Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is thrilled to announce that its Chairman, Dr. Hans Keirstead, is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland.

CollPlant Biotechnologies announced that Mr. Yehiel Tal, the Company’s CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.

Xilio Therapeutics, Inc. (Nasdaq: XLO) today highlighted recent advances across its clinical pipeline and reported encouraging preliminary safety data from the first three dose levels in the ongoing Phase 1 trial evaluating XTX301, a tumor-activated IL-12, in patients with advanced solid tumors.

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS) is pleased to announce that Vivos is seeing positive preliminary metrics following its November 28, 2023 announcement regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.

Medison Pharma announced their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo®, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.

Ambrx Biopharma, Inc., or Ambrx, announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.

Rockwell Medical, Inc. announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP.